Breaking News
-
Jul 31 2020Boehringer Ingelheim launches NexGard® and Broadline® in India for comprehensive parasite control in companion animals
Boehringer Ingelheim, a leading global human pharma and animal healthcare…
Read more -
Jul 12 2020EMA’s committee issues opinion to take measures to limit presence of nitrosamines in medicines
EMA’s human medicines committee (CHMP) has issued an opinion requiring…
Read more -
Jul 12 2020IDEAYA Biosciences begins patient dosing in phase 1 combination study of IDE196 and binimetinib to treat MUM
IDEAYA Biosciences, an oncology-focused precision medicine company committed to the…
Read more -
Jul 12 2020NIH researchers reframe dog-to-human aging comparisons
One of the most common misconceptions is that one human…
Read more -
Jul 12 2020Philip Morris gets US FDA marketing nod for IQOS tobacco heating system with ‘reduced exposure’ information
The US Food and Drug Administration (FDA) authorized the marketing…
Read more -
Jul 12 2020Sedana Medical phase III study of IsoConDa meets primary endpoint
Sedana Medical AB (publ), a medical device company, announced a…
Read more -
Jul 06 2020Digital Pharma—Beyond the Pill. Digital medicines and digital health
Digitalization is playing an increasingly important role in drug-development and…
Read more -
Jul 01 2020Pharma Business propels Beaufond PLC’s 3rd Quarter 62.16 % increase in EBITDA to USD 17.736 million of against USD 10.937 million to the corresponding period of last year.
Beaufond PLC continues to pursue its development strategy and once…
Read more -
Jun 06 2020INOVIO, IVI & Seoul National University Hospital partner to begin phase 1/2 trial of INOVIO’s COVID-19 DNA vaccine in South Korea
INOVIO, the International Vaccine Institute (IVI), and Seoul National University…
Read more -
Jun 06 2020Novartis phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair Breezhaler vs free combo of two existing inhaled treatments in uncontrolled asthma
Novartis announced that full results from the phase IIIb ARGON…
Read more
